Pharmaceuticals

Merck Initiates Shorespan-007 Clinical Trial of Bomedemstat for Essential Thrombocythemia

bexib
By bexib 0 Min Read

Shorespan-007 will enroll approximately 300 patients with essential thrombocythemia and compare bomedemstat to the current standard of care, hydroxyurea.

You Might Also Like

What Kamala Harris thinks about three big drug issues

Domino Data Lab Announces Computing Coalition to Combat Data Silos in Clinical Research

Mining clues from libraries of brain tissue samples, Cerevance takes a precision approach to central nervous system diseases

As the federal government cracks down on PBMs over drug costs, big pharma companies could lose pressure

BD to acquire Edwards Lifesciences’ Critical Care Products Group for $4.2 billion

Share This Article
Previous Article 2:00 PM The Water Cooler August 27, 2024 | Naked Capitalism
Next Article Negotiating in a chaotic mixed economy
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Cambodian Bakong tourist app now supports Visa cards for payment
Fintech
Techcombank’s digital channels drive growth to 15 million users in 2024
Fintech
Top 10 largest fintech acquisitions in Southeast Asia
Fintech
Revolut launches robo-advisor in Singapore
Fintech